• Saved
• Promoted

TITLE: Clinical application of liquid biopsy in non-Hodgkin lymphoma
SUMMARY: In the case of DLBCL or any other (less) common NHL subtype, tissue diagnosis is the gold standard. Tissue samples, however, are harvested by surgical resection or lymph node puncture, which both carry risks inherent to invasive procedures. Moreover, tissue samples are static in their sampling and reflect only results local to biopsy. Liquid biopsies [LB], however, are noninvasive and can monitor dynamic measures reflecting disease progression.
“The noninvasive, easy-to-obtain, and reproducible characteristics of LB provide unique opportunities for the dynamic assessment of NHL-related changes. This method improves the diagnostic accuracy of identifying disease subtypes and prognosis and can be used to provide better-individualized treatment for patients,” according to the authors of the current review.
“More importantly, LB can be used to fill the gaps in the monitoring of response to treatment and the detection of MRD in NHL. The real-time monitoring of treatment and timely adjustments to treatment plans based on identifiable characteristics will provide enhanced benefits to patients. The accurate early detection of disease recurrence can also enable clinicians to perform remedial treatments earlier,” they concluded.
QUESTION:
What notable experiences have you had with liquid biopsy? In what settings is it particularly useful?

• 0
• 2
• 0
• 0